

IN THE CLAIMS

Please amend the claims as follows:

1-10. (Cancelled)

11. (Currently Amended) An ocular implant comprising:

[[an]] a porous or absorbent implant body ~~[[.]]including a porous or absorbent material[[.]]~~ the porous or absorbent implant body extending from a proximal end portion, configured to seat at or near a lacrimal punctum when implanted, to a distal end portion, configured for insertion through the lacrimal punctum into a lacrimal canaliculus when implanted; and

an active agent disposed entirely throughout the porous or absorbent ~~material of the~~ implant body, the active agent ~~delivered~~ deliverable on a sustained release basis to tissue at or near one or both of ~~a first location proximal to an eye or a second location distal to the eye~~ nasolacrimal system via an exterior surface portion of the implant body.

12. (Cancelled)

13. (Withdrawn) The ocular implant of claim 11, wherein the distal end portion of the implant body includes a stem, the stem configured to insert into the lacrimal canaliculus and including the exterior surface portion of the implant body releasing the active agent.

14. (Previously Presented) The ocular implant of claim 11, wherein the proximal end portion of the implant body includes an outer stopper structure configured to seat against the lacrimal punctum, the outer stopper structure including the exterior surface portion of the implant body releasing the active agent and having a size greater than an aperture size of the lacrimal punctum.

15. (Previously Presented) The ocular implant of claim 11, wherein the active agent includes a medicine.

16. (Withdrawn – Currently Amended) The ocular implant of claim 15, wherein the active agent includes a medicine selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimatoprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a ~~medication~~ medication for treating hypertension; atenolol; nifedipine; hydrochlorothiazide; cyclosporine; and olopatadine.
17. (Previously Presented) The ocular implant of claim 11, wherein the active agent includes a medication for treatment of an eye.
18. (Withdrawn) The ocular implant of claim 11, wherein the implant body includes a lumen extending from the proximal end portion to the distal end portion, the lumen configured for a passage of tear fluid therethrough.
19. (Withdrawn – Currently Amended) The ocular implant of claim 18, wherein the sustained release of the active agent to tissue at or near the ~~second location distal to the eye~~ nasolacrimal system is via an interior lumen surface portion of the implant body.
20. (Cancelled)
21. (Previously Presented) The ocular implant of claim 11, wherein the exterior surface portion of the implant body releasing the active agent is disposed at or near the proximal end portion of the implant body, the active agent configured to treat the eye.
22. (Previously Presented) The ocular implant of claim 21, wherein the exterior surface portion of the implant body releasing the active agent is configured to provide the sustained release to tissue at or near the eye for a time period between 3-6 months after implant.
23. (Withdrawn) The ocular implant of claim 21, wherein the exterior surface portion of the implant body releasing the active agent is in the form of one or more agent-discharging bands.

24. (Withdrawn – Currently Amended) The ocular implant of claim 11, wherein the exterior surface portion of the implant body releasing the active agent is disposed at or near the distal end portion, the active agent configured to ~~be treat delivered to~~, at least in part, the nasolacrimal system.

25. (Withdrawn) The ocular implant of claim 24, wherein the exterior surface portion of the implant body releasing the active agent is in the form of one or more agent-discharging bands.

26. (Withdrawn) The ocular implant of claim 11, wherein the exterior surface portion of the implant body releasing the active agent is disposed on all exterior surfaces of the implant body.

27. (Withdrawn) The ocular implant of claim 11, wherein the distal end portion of the implant body includes an inner stopper structure, the inner stopper structure configured to at least partially secure an implant location of the implant body.

28. (Withdrawn) The ocular implant of claim 13, wherein the exterior surface portion of the implant body releasing the active agent is configured to provide the sustained release to tissue of the canaliculus wall.

29. (Previously Presented) The ocular implant of claim 14, wherein the outer stopper structure is configured to completely seal the lacrimal punctum against a flow of tear fluid therethrough.

30. (Currently Amended) An ocular implant comprising:

[[an]] a porous or absorbent implant body[[.]] ~~including a porous or absorbent material~~[[.]] sized and shaped for at least partial insertion into a lacrimal canaliculus; and
the porous or absorbent implant body incorporating an active agent from a proximal end portion of the porous or absorbent material ~~included in~~ the implant body, configured to seat at or near a lacrimal punctum when implanted, to a distal end portion of the porous or absorbent material ~~included in~~ the implant body, configured for insertion through the lacrimal punctum into

the lacrimal canaliculus when implanted, the active agent ~~delivered~~ deliverable to tissue at or near one or both of ~~a first location proximal to an eye or a second location proximal a~~ nasolacrimal system.

31. (Previously Presented) The ocular implant of claim 30, wherein an exterior surface of the implant body at the proximal end portion releases the active agent to treat the eye.

32. (Withdrawn – Currently Amended) The ocular implant of claim 30, wherein an exterior surface of the implant body at the distal end portion releases the active agent ~~to treat~~ for delivery to the nasolacrimal system.

33. (Previously Presented) The ocular implant of claim 30, wherein the distal end portion of the implant body includes an inner stopper structure configured to at least partially secure an implant location of the implant body.

34. (Previously Presented) The ocular implant of claim 30, wherein the entire implant body is substantially saturated with the active agent.

35. (Withdrawn) The ocular implant of claim 34, wherein all exterior surfaces of the implant body release the active agent.

36. (Withdrawn – Currently Amended) The ocular implant of claim 30, wherein the active agent includes a medicine selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimatoprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a ~~medication~~ medication for treating hypertension; atenolol; nifedipine; hydrochlorothiazide; cyclosporine; and olopatadine.

37. (Currently Amended) The ocular implant of claim 11, wherein the implant body is substantially inert.

38. (Previously Presented) The ocular implant of claim 11, wherein the active agent includes a medication for the treatment of glaucoma.

39. (Currently Amended) The ocular implant of claim 38, wherein the medication for the treatment of glaucoma includes ~~a topical prostaglandin derivative~~ travaprost or bimataprost.

40. (Currently Amended) The ocular implant of claim ~~[[39]]~~ 38, wherein the ~~topical prostaglandin derivative includes at least one of~~ medication for the treatment of glaucoma includes latanoprost~~[[,]] travaprost, or bimataprost~~.

41. (Previously Presented) The ocular implant of claim 30, wherein the active agent is administered on a sustained release basis for a time period of between 3-6 months after implant.

42. (Previously Presented) The ocular implant of claim 30, wherein the active agent includes a medication for the treatment of glaucoma.

43. (Currently Amended) The ocular implant of claim 42, wherein the medication for the treatment of glaucoma includes ~~a topical prostaglandin derivative~~ travaprost or bimataprost.

44. (Currently Amended) The ocular implant of claim ~~[[43]]~~ 42, wherein the ~~topical prostaglandin derivative includes at least one of~~ medication for the treatment of glaucoma includes latanoprost~~[[,]] travaprost, or bimataprost~~.